<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447876</url>
  </required_header>
  <id_info>
    <org_study_id>A-94-52120-100</org_study_id>
    <nct_id>NCT00447876</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis</brief_title>
  <official_title>Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the hypothesis that the analgesic effect of a single injection
      of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar
      fasciitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of score value on the visual analogue scale for pain during weight-bearing in the last 48 hours in week 6. &quot;Responder&quot; is defined as a reduction in score value of ≥ 50%</measure>
    <time_frame>Week 6 after injection versus baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gerbershagen Score</measure>
    <time_frame>Week 0, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity on the Visual Analogue Scale</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pressure pain with algorimeter: most severe pain experienced on the medial hindfoot</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Force measurement by Brunner (Grade 0-5)</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment by the investigator and the patient</measure>
    <time_frame>Week 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of study drug (recording of drug side-effects)</measure>
    <time_frame>Week 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Plantar Fasciitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum type A toxin (Dysport®)</intervention_name>
    <description>Placebo: 0,9% sodium chloride, 2 ml Drug: Botulinum type A toxin (Dysport®) 200 Units / 2 ml injected at the root of the plantar fascia</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic plantar fasciitis (duration of disorder at least 4 months)

          -  At least 4 points on the visual analogue scale (0-10) for the most severe pain within
             the last 48 hours

          -  At least 2 previous unsuccessful conservative therapies

          -  Age 18 and older

        Exclusion Criteria:

          -  Rheumatoid diseases (M. Bechterew, chronic polyarthritis, psoriasis-arthritis, para
             /post-infectious arthritis etc.)

          -  Previous surgery in the affected area of the foot

          -  Pre-treatment with Botulinum toxin A (only de novo patients)

          -  Prohibited concomitant treatment: local injections during the study and 2 weeks prior
             to start of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert Van Eijk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Charite, Campus Virchow, Musculoskeletal Centre, Orthopedic Clinic</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Practice Biberburg</name>
      <address>
        <city>Berlin</city>
        <zip>14089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Practice</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Orthopädie und Rheumatologie, Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthocentre Munich</name>
      <address>
        <city>Munich</city>
        <zip>81547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Practice</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <lastchanged_date>October 20, 2009</lastchanged_date>
  <firstreceived_date>March 13, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Bert Van Eijk</name_title>
    <organization>Ipsen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
